ArticleBMC endocrine disorders2026
Association of HbA1c levels with neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and platelet-to-lymphocyte ratio in patients with diabetes mellitus: a case-control study.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Two-Time-Point Inflammatory Status Patterns and the Risk of Incident Diabetes: A Cohort Study Based on CHARLS.Healthcare (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prevalence of diabetes mellitus in the general population has been increasing in recent years, and diabetes-related complications contribute substantially to morbidity, mortality, and healthcare system burden. This study aimed to evaluate the relationship between glycated hemoglobin (HbA1c) levels and inflammatory markers, including the neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR), in individuals diagnosed with type 2 diabetes mellitus (T2DM).
methodsThis retrospective case-control with longitudinal follow-up study included 138 patients with T2DM followed at the Internal Medicine Outpatient Clinic of Başakşehir Çam and Sakura City Hospital (HbA1c > 7%: n = 37; HbA1c < 7%: n = 101) and 118 healthy control subjects. HbA1c, white blood cell (WBC) count, NLR, MLR, and PLR values obtained at baseline and follow-up outpatient visits were retrospectively retrieved from the hospital information system and compared between groups.
resultsGlucose and HbA1c levels differed significantly among the groups, with the highest values observed in the uncontrolled diabetes group (p < 0.001). WBC and neutrophil counts were also significantly higher in patients with uncontrolled diabetes (p < 0.001). Monocyte counts, as well as NLR and MLR levels, were significantly increased in this group (p < 0.05). At the third-month follow-up, patients in the uncontrolled diabetes group exhibited significant changes in glucose, HbA1c, neutrophil, lymphocyte, NLR, and PLR levels (p < 0.05), whereas the change in MLR did not reach statistical significance (p = 0.083). Correlation analysis demonstrated significant positive associations between diabetes duration, glucose, and HbA1c levels and both NLR and MLR (r = 0.316-0.354, p < 0.001). Additionally, moderate positive correlations were observed among NLR, MLR, and PLR at both baseline and third-month measurements (p < 0.001).
conclusionNLR, MLR, and PLR are low-cost and easily accessible inflammatory markers that change in parallel with HbA1c levels and may be useful for monitoring glycemic control and disease progression in T2DM. These findings support the potential clinical utility of inflammation-based risk assessment in patients with type 2 diabetes mellitus. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.